Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Rating of “Hold” from Analysts

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have earned an average rating of “Hold” from the twenty-three brokerages that are presently covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $20.1875.

A number of brokerages recently issued reports on NTLA. Citigroup reaffirmed a “market outperform” rating on shares of Intellia Therapeutics in a report on Monday, June 15th. New Street Research set a $25.00 price objective on shares of Intellia Therapeutics in a research report on Monday, June 15th. Wolfe Research cut shares of Intellia Therapeutics to an “underperform” rating and set a $9.00 target price for the company. in a report on Wednesday. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $49.00 target price on shares of Intellia Therapeutics in a research report on Tuesday, June 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Tuesday, April 21st.

Insider Buying and Selling at Intellia Therapeutics

In other news, EVP Edward J. Dulac III sold 4,677 shares of the business’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total value of $84,186.00. Following the completion of the sale, the executive vice president directly owned 156,286 shares of the company’s stock, valued at approximately $2,813,148. The trade was a 2.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Michael P. Dube sold 2,641 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total value of $44,315.98. Following the completion of the sale, the chief accounting officer directly owned 66,886 shares of the company’s stock, valued at approximately $1,122,347.08. This trade represents a 3.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 3.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its holdings in shares of Intellia Therapeutics by 154.1% in the first quarter. AQR Capital Management LLC now owns 90,875 shares of the company’s stock valued at $646,000 after acquiring an additional 55,118 shares during the period. Woodline Partners LP acquired a new position in shares of Intellia Therapeutics in the 1st quarter valued at $171,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Intellia Therapeutics by 8.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company’s stock valued at $3,709,000 after acquiring an additional 38,521 shares during the period. Creative Planning raised its position in Intellia Therapeutics by 12.9% in the 2nd quarter. Creative Planning now owns 33,102 shares of the company’s stock valued at $310,000 after purchasing an additional 3,795 shares during the last quarter. Finally, Cetera Investment Advisers raised its position in Intellia Therapeutics by 47.4% in the 2nd quarter. Cetera Investment Advisers now owns 33,532 shares of the company’s stock valued at $315,000 after purchasing an additional 10,785 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Price Performance

Shares of NASDAQ NTLA opened at $13.04 on Thursday. The business has a 50-day moving average of $14.38 and a two-hundred day moving average of $13.40. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -3.68 and a beta of 1.77. Intellia Therapeutics has a 1 year low of $7.95 and a 1 year high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.11. The business had revenue of $15.05 million for the quarter, compared to the consensus estimate of $13.81 million. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.During the same quarter in the prior year, the business posted ($1.10) EPS. As a group, equities research analysts expect that Intellia Therapeutics will post -3.18 earnings per share for the current year.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical?stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease?causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.